Charts Week Month
Heat map Market Overview
Sentiment Sectors ETFs
Earnings News Earnings Movers The Drift Pivots
The Big Picture Breakouts Full Earnings News
Investor Services

Earnings are the driver of stock prices and the right earnings information can help longer-term investors significantly outperform the overall stock market.

The Whisper Report ® A look at upcoming earnings from both a top-down and bottom-up basis. Grades Stocks with A+ Earnings Whisper Grades Have Significantly Outperformed the Stock Market. Call Summaries Conference call summaries. AI Call Analysis AI Conference call analysis. Earnings Daily earnings results. Guidance Daily earnings guidance from companies. Reactions Earnings Screener Short Interest Report When the short trade becomes crowded.
Trader Service

Short-term earnings trading tools built around expectations, sentiment, quantitative studies, volatility, and post-earnings drift.

Trading Strategy The current strategy based on a broad market analysis and data. Earnings Whisper Plays Combining research, sentiment, quantitative studies, and technical analysis for short-term trades. Scores Identifying the likely Earnings Announcement Premium. Power Ratings Earnings with enough power for a short-term Post-Earnings Announcement Drift. Whisperings ^TM Whisperings are comments from analysts about upcoming earnings releases. AI Call Rankings Find which companies had the strongest or weakest conference calls. Option Trades Volatility Options Activity Unusual options activity around earnings. Setups Unusual options activity around earnings. Reversals Unusual options activity around earnings. Spikes Unusual options activity around earnings.
Dashboard

ARVN Arvinas, Inc.

NASDAQ

$8.97

Arvinas, Inc. (ARVN) Earnings News

Earnings press releases and Earnings Whispers previews for Arvinas, Inc. (ARVN), newest first.

Tuesday August 4, 2026 7:00 AM ET

Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Tuesday July 28, 2026 7:00 AM ET

Arvinas to Report Second Quarter 2026 Financial Results on August 4, 2026

Thursday June 4, 2026 8:00 AM ET

Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease

Tuesday May 12, 2026 7:05 AM ET

Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update

Tuesday May 5, 2026 7:00 AM ET

Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026

Wednesday March 18, 2026 7:00 AM ET

Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days

Wednesday March 11, 2026 7:00 AM ET

Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders

Tuesday February 24, 2026 7:00 AM ET

Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Tuesday February 17, 2026 7:00 AM ET

Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026